Tectonic Therapeutic (NASDAQ:TECX) Stock Price Down 5.8% – Should You Sell?

Posted by Stanley Muller on Jul 8th, 2026

Tectonic Therapeutic, Inc. (NASDAQ:TECX – Get Free Report) shares fell 5.8% during mid-day trading on Monday . The stock traded as low as $35.79 and last traded at $35.73. 136,417 shares changed hands during mid-day trading, a decline of 52% from the average daily volume of 285,415 shares. The stock had previously closed at $37.93.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on TECX shares. Wall Street Zen cut shares of Tectonic Therapeutic from a “sell” rating to a “strong sell” rating in a research report on Saturday, April 18th. Stifel Nicolaus assumed coverage on shares of Tectonic Therapeutic in a research report on Monday, April 13th. They issued a “buy” rating and a $75.00 price target on the stock. Raymond James Financial raised Tectonic Therapeutic from an “outperform” rating to a “strong-buy” rating and increased their price objective for the stock from $76.00 to $81.00 in a research note on Tuesday, May 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Tectonic Therapeutic in a research report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $79.40.

View Our Latest Report on Tectonic Therapeutic

Tectonic Therapeutic Stock Performance

The company’s 50 day simple moving average is $29.99 and its 200 day simple moving average is $26.79. The stock has a market cap of $668.75 million, a PE ratio of -7.93 and a beta of 3.21.

Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.18). Equities research analysts expect that Tectonic Therapeutic, Inc. will post -5.46 earnings per share for the current year.

Insider Transactions at Tectonic Therapeutic

In other Tectonic Therapeutic news, insider Marcella K. Ruddy sold 1,065 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $30.00, for a total transaction of $31,950.00. Following the sale, the insider owned 67,682 shares in the company, valued at $2,030,460. This represents a 1.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 39.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TECX. Baker BROS. Advisors LP increased its stake in Tectonic Therapeutic by 803.4% in the fourth quarter. Baker BROS. Advisors LP now owns 903,400 shares of the company’s stock valued at $18,845,000 after acquiring an additional 803,400 shares during the last quarter. Aberdeen Group plc boosted its holdings in shares of Tectonic Therapeutic by 220.6% in the 4th quarter. Aberdeen Group plc now owns 1,141,824 shares of the company’s stock worth $23,818,000 after purchasing an additional 785,648 shares in the last quarter. Braidwell LP purchased a new position in shares of Tectonic Therapeutic in the 3rd quarter worth about $11,561,000. First Light Asset Management LLC bought a new position in shares of Tectonic Therapeutic during the 1st quarter valued at about $20,022,000. Finally, Orbimed Advisors LLC purchased a new position in shares of Tectonic Therapeutic during the 4th quarter valued at about $11,986,000. 62.63% of the stock is currently owned by institutional investors.

Tectonic Therapeutic Company Profile

(Get Free Report)

Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.